Bli medlem
Bli medlem

Du är här

2021-02-24

BioStock: Restart for Chordate Medical's migraine study

Yesterday, Chordate Medical announced that the company's migraine study has resumed in Finland after being paused for a number of months due to the Covid-19 pandemic. The goal is now to complete the migraine study in July so that Chordate Medical's method can be CE marked as a treatment for chronic migraine.

Read the full article at biostock.se:

https://www.biostock.se/en/restart-for-chordate-medicals-migraine-study/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.